Cover Image

Pericardial events associated with ibrutinib‐based therapies for chronic lymphocytic leukaemia in two landmark trials

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Bita Fakhri, Victoria Wang, Gabriela Perez‐Burbano, Anna Wall, Sumithra Mandrekar, Sameer A. Parikh, Jennifer Woyach, Tait Shanafelt
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	British Journal of Haematology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single‐institution study
by: Bita Fakhri, et al.
Published: (2025)

Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
by: Tuan Hoang, et al.
Published: (2025)

Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia
by: Nilanjan Ghosh, et al.
Published: (2024)

Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia
by: Talha Munir, et al.
Published: (2025)

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab
by: David J. Allsup, et al.
Published: (2026)

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
by: Francesca Perutelli, et al.
Published: (2025)

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype
by: Andrea Serafin, et al.
Published: (2025)

Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
by: M. S. Davids, et al.
Published: (2024)

Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction
by: Chenyu Lin, et al.
Published: (2024)

Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study
by: Yi‐Wei Lee, et al.
Published: (2026)

Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells
by: Radu Chiriac, et al.
Published: (2025)

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia
by: Tony Marchand, et al.
Published: (2024)

The Mozart effect in chronic myeloid leukaemia
by: Jesper Stentoft
Published: (2024)

An old leukaemia in young patients—Genetic characteristics of paediatric chronic myeloid leukaemia
by: Markus Metzler, et al.
Published: (2025)

γδ and αβ T‐cell large granular lymphocytic leukaemia have similar characteristics and outcomes
by: Rui Cui, et al.
Published: (2024)

The chromosomal translocation t (1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1 :: IRF4 fusion
by: Sandrine Jayne, et al.
Published: (2024)

Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
by: Mengyao Yuan, et al.
Published: (2025)

Dapsone for paediatric chronic immune thrombocytopenia: Short report from a tertiary centre in South India
by: Niteesh Bharadwaj, et al.
Published: (2024)

Differences in adverse events between manuscript and drug labels for myeloma T‐cell‐redirecting therapies
by: Bita Bashy, et al.
Published: (2025)

Risk factors and reasons for switching from front‐line therapy in the Italian chronic myeloid leukaemia network: A cohort study
by: Massimo Breccia, et al.
Published: (2026)

Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide
by: Xiaohui Zhang, et al.
Published: (2024)

A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma
by: John Kuruvilla, et al.
Published: (2024)

Humoral and functional SARS ‐ CoV ‐2‐specific T‐cell responses elicited in chronic lymphocytic leukaemia patients with GEO ‐ CM04S1 a synthetic MVA ‐vectored COVID ‐19 vaccine
by: Sandra Ortega‐Francisco, et al.
Published: (2025)

Clinical and molecular characteristics of paediatric mature B‐cell acute lymphocytic leukaemia and non‐Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups
by: Jie Zhao, et al.
Published: (2025)

Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients
by: Vincent Alcazer, et al.
Published: (2024)

A phase 2 study of single agent ibrutinib for first‐line treatment of chronic graft‐versus‐host disease: A new paradigm and lessons learned
by: Najla El Jurdi, et al.
Published: (2025)

A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
by: Ricardo D. Parrondo, et al.
Published: (2024)

Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia‐related changes: Post hoc analysis of the QUAZAR AML ‐001 trial
by: Maria Teresa Voso, et al.
Published: (2025)

Introducing a prognostic score for successful treatment‐free remission in chronic myeloid leukaemia
by: Simone Claudiani, et al.
Published: (2026)

Correction to ‘A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia’
Published: (2024)

Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights
by: Boaz Nachmias, et al.
Published: (2025)

Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study Group
by: Herbert Pichler, et al.
Published: (2024)

Multiple small‐dose infusions of G‐CSF‐mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia
by: Fei Yang, et al.
Published: (2024)

Peripheral blood profiling of azacitidine's hypomethylation: Advancing precision medicine in juvenile chronic myelomonocytic leukaemia
by: Pasquale Niscola
Published: (2025)

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
by: Isla M. Johnson, et al.
Published: (2024)

The efficacy of targeted and immune‐based therapies in adults with TP53‐mutated acute lymphoblastic leukaemia
by: Hoda Pourhassan, et al.
Published: (2025)

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
by: Wei‐Ying Jen, et al.
Published: (2024)

Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study
by: Alessandro Costa, et al.
Published: (2026)

Dynamic improvement of the treatment‐free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia
by: Mai Fujita, et al.
Published: (2026)

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
by: Michael R. Savona, et al.
Published: (2025)